MA40902B1 - Vaccins hpv16 thérapeutiques - Google Patents

Vaccins hpv16 thérapeutiques

Info

Publication number
MA40902B1
MA40902B1 MA40902A MA40902A MA40902B1 MA 40902 B1 MA40902 B1 MA 40902B1 MA 40902 A MA40902 A MA 40902A MA 40902 A MA40902 A MA 40902A MA 40902 B1 MA40902 B1 MA 40902B1
Authority
MA
Morocco
Prior art keywords
therapeutic
vaccines
hpv16 vaccines
therapeutic hpv16
nucleic acid
Prior art date
Application number
MA40902A
Other languages
English (en)
Other versions
MA40902A (fr
Inventor
Jerôme Custers
Gerrit Scheper
Koen Oosterhuis
Taco Uil
Selina Khan
Evelien Bunnik
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52020908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40902(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA40902A publication Critical patent/MA40902A/fr
Publication of MA40902B1 publication Critical patent/MA40902B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)

Abstract

L'invention concerne des constructions d' acides nucléiques et des polypeptides de concepteur pouvant être utilisés en tant que vaccins thérapeutiques contre hpv16.
MA40902A 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques MA40902B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14191660 2014-11-04
PCT/EP2015/075516 WO2016071306A1 (fr) 2014-11-04 2015-11-03 Vaccins thérapeutiques contre le vph16
EP15791556.2A EP3215187B1 (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques

Publications (2)

Publication Number Publication Date
MA40902A MA40902A (fr) 2017-09-13
MA40902B1 true MA40902B1 (fr) 2018-12-31

Family

ID=52020908

Family Applications (2)

Application Number Title Priority Date Filing Date
MA046378A MA46378A (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques
MA40902A MA40902B1 (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA046378A MA46378A (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques

Country Status (33)

Country Link
US (4) US9701721B2 (fr)
EP (2) EP3215187B1 (fr)
JP (2) JP6325751B2 (fr)
KR (1) KR20170083562A (fr)
CN (1) CN107075521B (fr)
AR (1) AR102527A1 (fr)
AU (2) AU2015341926B2 (fr)
BR (1) BR112017009177A2 (fr)
CA (1) CA2965562C (fr)
CL (1) CL2017001089A1 (fr)
CO (1) CO2017004838A2 (fr)
CY (1) CY1121377T1 (fr)
DK (1) DK3215187T3 (fr)
EA (1) EA035461B1 (fr)
ES (1) ES2697903T3 (fr)
HR (1) HRP20181895T1 (fr)
HU (1) HUE040440T2 (fr)
IL (1) IL251895B (fr)
LT (1) LT3215187T (fr)
MA (2) MA46378A (fr)
MD (1) MD3215187T2 (fr)
MX (1) MX2017005788A (fr)
MY (1) MY181175A (fr)
NZ (1) NZ730802A (fr)
PL (1) PL3215187T3 (fr)
PT (1) PT3215187T (fr)
RS (1) RS58080B1 (fr)
SA (1) SA517381457B1 (fr)
SG (1) SG11201702997YA (fr)
SI (1) SI3215187T1 (fr)
TW (2) TWI731654B (fr)
WO (1) WO2016071306A1 (fr)
ZA (1) ZA201703055B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040440T2 (hu) 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
CA2995740A1 (fr) 2015-08-20 2017-02-23 Janssen Vaccines & Prevention B.V. Vaccins therapeutiques contre le vph 18
BR112018072372A2 (pt) * 2016-05-02 2019-02-19 Janssen Vaccines & Prevention B.V. combinações de vacina terapêutica contra o hpv
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
AR113124A1 (es) 2017-09-23 2020-01-29 Boehringer Ingelheim Vetmedica Gmbh Sistema de expresión de paramyxoviridae
WO2019164970A1 (fr) * 2018-02-20 2019-08-29 Emory University Protéines hpv, anticorps, et leurs utilisations dans la gestion de la croissance cellulaire épithéliale anormale
WO2019178005A2 (fr) * 2018-03-12 2019-09-19 Sqz Biotechnologies Company Procédés de traitement de maladies associées au hpv
US11713469B2 (en) 2018-07-20 2023-08-01 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing Zika antigen with improved productivity
CN108992665B (zh) * 2018-08-06 2021-11-19 南京颂悦生物科技有限公司 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗
CN108939064B (zh) * 2018-08-06 2021-12-10 南京颂悦生物科技有限公司 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
KR20220068242A (ko) 2019-09-20 2022-05-25 트랜스진 Hpv 폴리펩티드 및 il-2를 암호화하는 폭스바이러스와 항-pd-l1 항체의 조합
US20230277645A1 (en) * 2020-04-02 2023-09-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia
WO2021209897A1 (fr) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Vaccins à base de psma et de steap1 et leurs utilisations
CA3182703A1 (fr) * 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration de vecteurs adenoviraux homologues
US11865170B2 (en) 2020-11-24 2024-01-09 Papivax Biotech Inc. DNA vaccine for human papillomavirus and method for using the same
KR20240099266A (ko) * 2021-10-22 2024-06-28 이노비오 파마수티컬즈, 인크. 항문 고등급편평상피내병변(hsil)을 치료하기 위한 조성물 및 방법

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (fr) 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
WO1995034671A1 (fr) 1994-06-10 1995-12-21 Genvec, Inc. Systemes de vecteurs adenoviraux et lignees cellulaires complementaires
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (fr) 1996-04-26 2007-08-14 National Research Council Of Canada Lignees de cellules complements e1 de l'adenovirus
WO1998039411A1 (fr) 1997-03-04 1998-09-11 Baxter International Inc. Lignees cellulaires de complementation de la region e1 d'un adenovirus
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
PT1816204E (pt) 1999-05-17 2011-01-24 Crucell Holland Bv Adenovírus recombinante do serótipo ad26
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
PT1214097E (pt) * 1999-09-16 2009-10-19 Eisai Inc Ácidos nucleicos que codificam polipéptidos de poliepitopos
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU2002211524B2 (en) 2000-10-04 2007-03-22 The Trustees Of The University Of Pennsylvania Highly expressible genes
WO2002042480A2 (fr) 2000-11-23 2002-05-30 Bavarian Nordic A/S Variant du virus de la vaccine modified vaccinia ankara
CA2446110C (fr) 2001-05-01 2013-06-25 National Research Council Of Canada Systeme destine a l'expression inductible dans des cellules eucariotes
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
WO2005089164A2 (fr) * 2003-12-31 2005-09-29 Pharmexa Inc. Induction de reponses immunitaires cellulaires au papillomavirus humain utilisant des compositions peptidiques et d'acides nucleiques
DE602005015332D1 (de) 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
JP5291341B2 (ja) 2004-11-08 2013-09-18 クロマジェニックス ベー ヴェー タンパク質を高レベルで発現する宿主細胞の選定
WO2007073513A2 (fr) 2005-11-10 2007-06-28 Genvec, Inc. Procede de propagation de vecteurs adenoviraux codant pour des produits geniques inhibiteurs
WO2007100908A2 (fr) 2006-02-28 2007-09-07 Vaxart, Inc Vecteurs anédoviraux chimériques
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
ATE518958T1 (de) * 2007-01-30 2011-08-15 Transgene Sa Zur impfung verwendetes papillomavirus-e2- polypeptid
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
DK2350268T3 (en) 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
EA023816B1 (ru) 2010-02-15 2016-07-29 Круселл Холланд Б.В. СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26
PL2604629T3 (pl) * 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
EP2780034A1 (fr) 2011-11-14 2014-09-24 Crucell Holland B.V. Immunisation primovaccination-rappel hétérologue à l'aide de vaccins à base du virus de la rougeole
EP2601968A1 (fr) 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum Acides polynucléiques dérivés du VPH pour thérapie
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
US10576141B2 (en) 2014-09-03 2020-03-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use
HUE040440T2 (hu) 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
CA2995740A1 (fr) * 2015-08-20 2017-02-23 Janssen Vaccines & Prevention B.V. Vaccins therapeutiques contre le vph 18
BR112018072372A2 (pt) * 2016-05-02 2019-02-19 Janssen Vaccines & Prevention B.V. combinações de vacina terapêutica contra o hpv

Also Published As

Publication number Publication date
SA517381457B1 (ar) 2021-03-11
JP6606571B2 (ja) 2019-11-13
MD3215187T2 (ro) 2019-02-28
EA201790976A1 (ru) 2017-09-29
EP3421046A1 (fr) 2019-01-02
AU2018282463B2 (en) 2020-09-10
TWI731654B (zh) 2021-06-21
HRP20181895T1 (hr) 2019-01-11
AU2015341926A1 (en) 2017-04-27
US10071151B2 (en) 2018-09-11
US20180344841A1 (en) 2018-12-06
PL3215187T3 (pl) 2019-04-30
JP6325751B2 (ja) 2018-05-16
JP2018148890A (ja) 2018-09-27
TW201617450A (zh) 2016-05-16
ZA201703055B (en) 2019-11-27
TWI694147B (zh) 2020-05-21
US9701721B2 (en) 2017-07-11
US20160122396A1 (en) 2016-05-05
KR20170083562A (ko) 2017-07-18
EA035461B1 (ru) 2020-06-19
CA2965562C (fr) 2023-11-21
MA46378A (fr) 2019-08-07
MY181175A (en) 2020-12-21
MA40902A (fr) 2017-09-13
RS58080B1 (sr) 2019-02-28
CN107075521B (zh) 2021-06-08
HUE040440T2 (hu) 2019-03-28
CO2017004838A2 (es) 2017-07-28
WO2016071306A1 (fr) 2016-05-12
DK3215187T3 (en) 2018-12-10
IL251895B (en) 2019-08-29
ES2697903T3 (es) 2019-01-29
MX2017005788A (es) 2017-08-02
PT3215187T (pt) 2018-11-27
AU2015341926B2 (en) 2018-09-27
CN107075521A (zh) 2017-08-18
CL2017001089A1 (es) 2017-12-29
LT3215187T (lt) 2018-12-27
SG11201702997YA (en) 2017-05-30
AU2018282463A1 (en) 2019-01-24
JP2017534286A (ja) 2017-11-24
EP3215187B1 (fr) 2018-08-29
EP3215187A1 (fr) 2017-09-13
BR112017009177A2 (pt) 2018-12-11
AR102527A1 (es) 2017-03-08
NZ730802A (en) 2021-12-24
US10555996B2 (en) 2020-02-11
TW202043476A (zh) 2020-12-01
CY1121377T1 (el) 2020-05-29
CA2965562A1 (fr) 2016-05-12
US20170281747A1 (en) 2017-10-05
US11040096B2 (en) 2021-06-22
US20200164057A1 (en) 2020-05-28
SI3215187T1 (sl) 2019-02-28
IL251895A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
MA40902B1 (fr) Vaccins hpv16 thérapeutiques
PH12019501931A1 (en) Anti-pdl1 antibody formulations
BR112018003019A2 (pt) vacinas terapêuticas contra hpv18
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
EA201891317A2 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
BR112017005381A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
MX2019004690A (es) Constructos de anticuerpos.
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
MX2018016362A (es) Formulaciones de anticuerpo anti-cd19.
BR112017005504A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX2017003121A (es) Formulaciones de anticuerpos.
EP3454908A4 (fr) Constructions ciblées et leurs formulations
MX2020012893A (es) Formulaciones de proteinas.
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
MY190102A (en) Tolerogenic dna vaccine
ZA201703467B (en) Methods of treating ocular conditions